# Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer

> **NCT00003656** · PHASE2 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 26 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **BIOLOGICAL:** recombinant interferon alfa
- **DRUG:** tretinoin liposome

## Key facts

- **NCT ID:** NCT00003656
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-01
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2022-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003656, "Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00003656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*